Efficacy and Safety of Lumateperone versus Atypical Antipsychotics as Adjunctive Therapy in Major Depressive Disorder

This course is part of the Psychiatry learning hub

FACULTY

Brittany Albright, MD, MPH
Founder and CEO, Sweetgrass Psychiatry
Mount Pleasant, South Carolina

Craig Chepke, MD, DFAPA
Adjunct Associate Professor of Psychiatry, Atrium Health
Medical Director, Excel Psychiatric Associates
Chief Medical Officer, Psych Congress
Huntersville, North Carolina

Andrew J. Cutler, MD
Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University
Chief Medical Officer, Neuroscience Education Institute
Lakewood Ranch, Florida

Rakesh Jain, MD, MPH
Clinical Professor, Texas Tech - Permian Basin
Lewisville, Texas

Greg Mattingly, MD
Psychiatrist, Washington University
Saint Charles, Missouri

Roger S. McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology, University of Toronto
Chairman and Executive Director, Brain and Cognition Discovery Foundation
Professor and Nanshan Scholar, Guangzhou Medical University
Adjunct Professor College of Medicine, Korea University
Toronto, Ontario, Canada

PROVIDER STATEMENT

Provided by HMP Education, an HMP Global Company.

INTENDED LEARNERS

This educational activity is specifically designed for psychiatrists, psychiatric/mental health nurse practitioners (NPs), advanced practice nurses (APRNs), physician associates (PAs), nurses, and the full multidisciplinary team of behavioral and mental health professionals, who seek to improve the care of patients with major depressive disorder.

LEARNING OBJECTIVES

After participating in this activity, learners should be better able to:

Assess treatment response status in patients with MDD using measurement-based approaches, including identification of residual symptoms
Evaluate current and late-breaking evidence on available treatment options for patients with MDD
Implement evidence-based strategies to optimize treatment selection for patients with MDD based on individual clinical presentation

ACTIVITY OVERVIEW

This on-demand webcast is available with synchronized slides and video/audio.

To be eligible for documentation of credit for each session attended, learners must participate in the activity, and complete the activity evaluation. Participants who complete the evaluation online within active dates of the training will receive documentation of credit. Your certificate may not load if you are accessing it from a smartphone, or if your browser settings do not allow a new tab/window to open.

Once a certificate has been claimed, physicians and pharmacists may elect for credits to be submitted on their behalf to their boards via additional fields that will appear within the Claim Certificate page. Credits must be submitted through this process to be reported to the American Board of Surgery and the National Association of Boards of Pharmacy.

Release Date: July 8, 2026
Expiration Date: July 8, 2027
Estimated Time to Complete: 0.75 hours

There is no fee associated with this activity.

HARDWARE/SOFTWARE REQUIREMENTS

The activity is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications.

CONTINUING EDUCATION

Joint Accreditation with commendation logo In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Note: This statement is not an indication of approved credits. Please see below for full accreditation details, including credit types and totals, for this activity.

PHYSICIANS

HMP Education designates this internet enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES

This continuing nursing education internet enduring activity awards 0.75 contact hours.

NURSE PRACTITIONERS

American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit^TMfrom organizations accredited by the ACCME.

PHYSICIAN ASSOCIATES

AAPA logo HMP Education has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 0.75 AAPA Category 1 credits. Approval is valid until July 8, 2027. PAs should only claim credit commensurate with the extent of their participation.

INTERNATIONAL RECOGNITION

Visit this link for countries and regions have reciprocity with the ACCME.

Visit this link for additional countries that accept ACCME-accredited continuing medical education (CME).

USE OF PROPRIETARY NAMES

This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters, or moderators and do not necessarily reflect the opinions of HMP Education.

DISCLAIMERS

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a provider-patient relationship. Medical advice of any nature should be sought from an individual’s own healthcare provider.

The opinions expressed in this educational activity are those of the faculty and are not attributable to HMP Global or any of its subsidiaries or affiliates. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to and mitigating all perceived or real relevant financial relationship (conflicts of interest) between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME and CPME.

Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
Any investigational, off-label, or non-FDA approved content or discussion

HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.

Education has been independently peer-reviewed to validate content, including any AI-supported elements, mitigate identified financial relationships (conflicts of interest), and ensure:

All recommendations involving clinical medicine are based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.

All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.

Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.

All relevant financial relationships have been mitigated.

FACULTY

The faculty have reported the following:

Brittany B. Albright, MD, MPH: Advisory Board—Bristol Myers Squibb, Johnson & Johnson/Janssen; Consultant—AbbVie Inc., Axsome, Johnson & Johnson/Janssen, Precision Genetics; Speaker’s Bureau—AbbVie Inc., Axsome, Johnson & Johnson/Janssen

Craig Chepke, MD, DFAPA: Advisory Board—AbbVie, Acadia, Alkermes, Axsome, Biogen, Bristol Myers Squibb, Corium, Idorsia, Intra-Cellular, Johnson & Johnson, Lundbeck, Moderna, Neurocrine, Noven, Otsuka, Sage, Sumitomo, Teva; Advisory Board (spouse): Bristol Myers Squibb, Otsuka; Consultant—AbbVie, Acadia, Alkermes, Axsome, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Corium, Intra-Cellular, Johnson & Johnson, Lundbeck, MedinCell, Moderna, Neurocrine, Noven, Otsuka, Sage, Sumitomo, Supernus, Teva; Research/Grant Support—Acadia, Axsome, Harmony, Neurocrine, Teva; Speaker’s Bureau—AbbVie, Acadia, Alkermes, Axsome, Boehringer Ingelheim, Bristol Myers Squibb, Corium, Intra-Cellular, Johnson & Johnson, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sumitomo, Teva

Andrew J. Cutler, MD: Advisory Board - AbbVie, Acadia, Actinogen, Alfasigma, Alkermes, Anavex Life Sciences, Arrivo BioVentures, Autobahn Therapeutics, Axsome, Aytu Biopharma, BioXcel, Boehringer Ingelheim, Bristol Myers Squibb, Collegium Pharmaceutical, Corium, Definium Therapeutics, 4M Therapeutics, Helus Pharma, Incannex Healthcare, Intra-Cellular Therapies, J&J Innovative Medicine, Jazz Pharma, Knight Therapeutics, Kye Pharmaceuticals, Kuvatris Therapeutics, LivaNova, Lundbeck, Luye Pharma, MapLight Therapeutics, Mentavi, Neumora, Neurocrine Biosciences, NeuroSigma, Noven, Otsuka, Relmada, Sensorium Therapeutics, Sirtsei Pharmaceuticals, Supernus, Teva, Thynk, Transneural Therapeutics, Tris Pharma, Vanda Pharmaceuticals, Vistagen; Consultant - AbbVie, Acadia, Actinogen, Alfasigma, Alkermes, Anavex Life Sciences, Arrivo BioVentures, Autobahn Therapeutics, Axsome, Aytu Biopharma, BioXcel, Boehringer Ingelheim, Bristol Myers Squibb, Collegium Pharmaceutical, Corium, Definium Therapeutics, 4M Therapeutics, Helus Pharma, Incannex Healthcare, Intra-Cellular Therapies, J&J Innovative Medicine, Jazz
Pharma, Knight Therapeutics, Kye Pharmaceuticals, Kuvatris Therapeutics, LivaNova, Lundbeck, Luye Pharma, MapLight Therapeutics, Mentavi, Neumora, NeurocrineBiosciences, NeuroSigma, Noven, Otsuka, Relmada, Sensorium Therapeutics, Sirtsei Pharmaceuticals, Supernus, Teva, Thynk, Transneural Therapeutics, Tris Pharma, Vanda Pharmaceuticals, Vistagen; Speaker's Bureau -- AbbVie, Alfasigma, Alkermes, Axsome, Aytu Biopharma, Boehringer Ingelheim, Bristol Myers Squibb, Collegium Pharmaceutical, Corium, Intra-Cellular Therapies, J&J Innovative Medicine, Knight Therapeutics, Kye Pharmaceuticals, Lundbeck, Luye Pharma, Neurocrine Biosciences, Noven, Otsuka, Supernus, Teva, Tris Pharma, Vanda Pharmaceuticals; Data Safety Monitoring Board - Compass Pathways; Stock options/equity: EMA Wellness, Evolution Research Group, 4M Therapeutics, Sensorium Therapeutics, Transneural Therapeutics

Rakesh Jain, MD, MPH: Advisory Board—Adamas, Alkermes, Corium, Eisai, Indivior, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Supernus, Takeda, Teva, Tris Pharmaceuticals; Consultant—AbbVie (Allergan), Acadia, Adamas, Alfasigma USA, Inc., Axsome, Corium, Cingulate Therapeutics, Eisai, Evidera, Impel NeuroPharma, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Osmotica, Otsuka, Pamlab, Pfizer, Sage Therapeutics, Shire, Sunovion, Supernus, Takeda, Teva; Grant/Research Support— AbbVie (Allergan), Lilly, Lundbeck, Otsuka, Pfizer, Shire, Takeda; Speakers Bureau—AbbVie (Allergan), Alkermes, Axsome, Corium, Eisai, Indivior, Intracellular Therapies, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Takeda, Teva, Tris Pharmaceuticals

Greg Mattingly, MD: Consultant—AbbVie, Acadia, Akilli, Alkermes, Angelini, Axsome, Biogen, Boehringer Ingelheim, Cerevel, Colegium, Corium, Eisai, Intracellular, Johnson & Johnson, Liva Nova, Lumos Labs, Lundbeck, Neurocrine, Noven, Otsuka, Redax, Relmada, Revibe, Roche, Sage, Sirona, Sunovion, Supernus, Takeda, Teva, and Tris Pharma; Research—AbbVie Inc., Acadia, Alkermes, Akilli, Alto Therapeutics, Avanir, Axsome, Boehringer Ingelheim, Cingulate, Click Therapeutics, Corium, Emalex, Idorsia, Intracellular, Johnson & Johnson, Lumos Labs, Medgenics, Neurocrine, NLS Pharma, Redax, Relmada, Roche, Sage, Sirtsei, Sumitomo, Sunovion, Supernus, Takeda, and Teva; Speakers Bureau—AbbVie Inc., Alkermes, Angelini, Axsome, Corium, Intracellular, Ironshore, Johnson & Johnson, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva and Tris Pharma

Roger S. McIntyre, MD, FRCPC: Consultant - Abbvie, Adhere Tech, Alkermes, Atai Life Sciences, Autobahn Therapeutics, Axsome, Bausch Health, Biogen, Bristol Myers Squibb (BMS), Boehringer Ingelheim, Eisai, Eli Lilly, GH Research, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, Neurawell, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Teva, Viatris; Speaker's Bureau -Abbvie, Adhere Tech, Alkermes, Atai Life Sciences, Autobahn Therapeutics, Axsome, Bausch Health, Biogen, Bristol Myers Squibb (BMS), Boehringer Ingelheim, Eisai, Eli Lilly, GH Research, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, Neurawell, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Teva, Viatris; Research Grant Support -CIHR/GACD/National Natural Science Foundation of China (NSFC), Milken Institute

CLINICAL REVIEWER

Craig Chepke, MD, DFAPA
Medical Director
Excel Psychiatric Associates
Huntersville, North Carolina

PLANNING COMMITTEE

Planning for this activity was conducted by faculty advisors. To further support the development of the content, additional information regarding professional roles, responsibilities, and teamwork was gathered through survey input from our target audience and/or a comprehensive literature review.

HMP Education planners and staff include Meaghan Benci, Kristin Cisezski, Haley Hartle, Samantha Joy, Josh Raitt, Randy Robbin, and Andrea Zimmerman, EdD, CHCP. No HMP Education staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).

ADA STATEMENT

HMP Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. Any participant in this educational activity who needs accommodation(s) may submit a request to the support team.

PRIVACY POLICY

HMP Education protects the privacy of personal and other information regarding participants, educational partners, and joint providers. HMP Education and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. HMP Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

COMMERCIAL SUPPORT

Supported by an educational grant from Johnson & Johnson.

CONTACT US

A blue square with white speech bubbles

Description automatically generated For immediate assistance, please explore our HMP Education Help Center or chat with our Virtual CE Assistant, which can answer most common questions related to claiming credits and the HMP Education website. If you have a question or grievance that cannot be answered by our Virtual CE assistant and Help Center, please contact the support team. Our accreditation and compliance team will respond to your inquiry within one business day.

Copyright © 2026 by HMP Education. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from HMP Education.

Rapid Reactions: Applying Emerging Evidence to Clinical Practice in MDD